Update of fecal markers of inflammation in inflammatory bowel disease.
about
Fecal biomarkers of intestinal health and disease in childrenSafety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trialIntestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.Association of gut microbiota with post-operative clinical course in Crohn's disease.Heat shock factor 2 levels are associated with the severity of ulcerative colitisS100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs.Biomarkers in inflammatory bowel disease: current practices and recent advances.Common beans and cowpeas as complementary foods to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for two randomized controlled trialsProgress in the treatment and outcome of pediatric inflammatory bowel disease patients.Crohn's and colitis in children and adolescents.Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancerNoninvasive measurement of intestinal inflammation after burn injury.Functions of S100 proteins.Diagnostic utility of faecal biomarkers in patients with irritable bowel syndromeImpact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease.Managing inflammatory bowel disease in adolescent patientsLactoferrin, a key molecule in immune and inflammatory processes.S100A12: a noninvasive marker of inflammation in inflammatory bowel disease.Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.Assessing disease activity in patients with ulcerative colitis.Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.Fecal biomarkers in inflammatory bowel disease.The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.Refractory inflammatory bowel disease-could it be an irritable bowel?Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases.Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry.Role of Lactobacilli and Lactoferrin in the Mucosal Cervicovaginal Defense.Neutrophil and Eosinophil Granule Proteins as Potential Biomarkers of Assessing Disease Activity and Severity in Patients With Ulcerative Colitis.An update on diagnostic and prognostic biomarkers in inflammatory bowel disease.Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings.S100A12 concentrations and myeloperoxidase activities are increased in the intestinal mucosa of dogs with chronic enteropathies.Granulocyte Macrophage Colony-Stimulating Factor Auto-Antibodies and Disease Relapse in Inflammatory Bowel Disease
P2860
Q27021773-9B655709-7191-4CEB-B798-8196338C6C13Q28483626-D4516501-0B4B-4406-A73B-4D6C3B396855Q33903892-242751AC-389A-48BF-958E-65B6098ECA94Q34960634-A1142C42-F9CC-4F29-9B04-EDC8B48AC80AQ35095575-694E46EE-1741-4C46-A9CB-FBAF9A170BD2Q35775425-CE2E51B8-1381-4AAE-9F3B-605FAC432A9FQ35840853-EEE190C1-69C5-4F21-ABD3-559431F7237CQ35844526-062BFFF4-9EC1-4FA0-8F5E-88CC9696AC48Q36056969-BD5DDBCC-FB11-4007-908B-C60620411135Q36378775-92F20103-64F8-4546-89A3-2597549B7B72Q36651474-4204647F-C64F-424F-A78F-0D580D4F899EQ36948314-3338A56B-39EA-43E9-8505-C7766B49004AQ37001259-7C5FC05F-AC16-4E9E-87DD-23FC6AAD516EQ37581340-4C81CA58-7028-45B5-9CF2-83B649796EFAQ37604067-DBC0E986-A0C6-4712-985A-E68AD5C6A3A2Q37641463-6B44AC1E-C2B8-401C-BDF1-661B2F452EA3Q37964040-E9245C22-D009-460C-9F9E-23AAAF518401Q38059248-8FFA5A61-3921-4967-903D-05AF73CC5211Q38089781-D49D1936-568C-4C00-99AA-0AC9FC2E317EQ38190411-77096919-78E4-444C-AC4B-2AB2E9B51CD1Q38519730-02CC5773-75F5-4103-9555-68E5242D2571Q38681986-DC3C61DA-1144-4703-AC8C-EFD975173744Q38742261-2D536CD3-6B83-4EAB-9C4D-59BCF0FBB934Q38977006-43EF4A8F-D211-47FB-85B9-657F5A76063FQ41587613-4A9A04BE-3C40-4761-877F-03BBE8D2B975Q43519792-5A0AC480-53FE-4BD8-BE56-172BC2AD5526Q43633176-89987A34-FEDD-4A79-AA42-884D709EF5F6Q47942430-FD62EF52-AFE6-4CE9-9D0E-9089D4CA6246Q49300617-B5C6AAD8-73AE-41A5-AD27-755E2DFCF809Q49513092-5888363F-1C95-4A34-AEC4-56A64697DC5DQ51739532-E159D648-C664-48BA-BEA7-A6C350C2B1A2Q53122615-7A630F17-D5D1-4D2E-8274-E8EEF618A72DQ53128510-944D18FF-0AB0-4923-A2CF-466022783406Q55409323-3B6D7557-8E4E-46D4-9582-48B50713E4B1Q55434420-026AECE1-D5E8-45C3-8ED2-F21E8C7EA2A2Q57913848-B81038E0-0467-4B4A-B769-3A16F16600D7
P2860
Update of fecal markers of inflammation in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update of fecal markers of inflammation in inflammatory bowel disease.
@en
Update of fecal markers of inflammation in inflammatory bowel disease.
@nl
type
label
Update of fecal markers of inflammation in inflammatory bowel disease.
@en
Update of fecal markers of inflammation in inflammatory bowel disease.
@nl
prefLabel
Update of fecal markers of inflammation in inflammatory bowel disease.
@en
Update of fecal markers of inflammation in inflammatory bowel disease.
@nl
P2093
P921
P1476
Update of fecal markers of inflammation in inflammatory bowel disease
@en
P2093
Andrew S Day
Dan Turner
Thomas A Judd
P304
P356
10.1111/J.1440-1746.2011.06846.X
P577
2011-10-01T00:00:00Z